

Sep 19, 2018

**NOVALIQ TO PRESENT AT THE OPHTHALMOLOGY FUTURES FORUMS
ON HOW TO BREAK THE VICIOUS CIRCLE OF DRY EYE DISEASE**

Heidelberg, Germany – Sep 19, 2018 – [Novaliq GmbH](#), a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, will present at the upcoming Ophthalmology Futures Forums in Vienna.

The [Ophthalmology Futures Forums](#) were established in 2012 to fill a void with regard to industry - investor meetings specifically for ophthalmology in Europe and Asia. The Forums focus on all aspects of global innovation in ophthalmology by connecting scientists, physicians, regulators, corporate leaders, venture capitalists and other investors who support the advancement of eye care.

In Europe, Dry Eye Disease (DED) has a prevalence of 8-17%. In the top five European countries (France, Germany, Italy, Spain, UK) more than 25 million people have symptoms of dry eyes and 18 million have been diagnosed with DED – yet only 3 million patients have been treated⁽¹⁾.

Current treatment options for patients in Europe are limited; so far only one drug was approved by the European Medicines Agency (EMA) for the treatment of severe keratitis in adults with DED. First choice in Europe remain artificial tears and eye lubricants. Outside Europe only few products are approved for the treatment of DED in US or Japan.

Dry eye has an effect on the quality of life and affects people from all walks of life. At a minimum, dry eye causes discomfort, but it can also cause disabling pain and vision disturbance. Recent publications highlight the correlation of dry eye and reading impairment^(2,3). New advances for this disease and genuine treatment options are clearly needed to break the vicious circle of Dry Eye Disease.

With a portfolio of best- and first-in-class products and two global clinical programs for CyclASol® and NOV03, Novaliq takes on the challenge to break the vicious circle of Dry Eye Disease. Results of the global clinical programs are expected to be communicated in October.

“Dry Eye Disease causes more than discomfort, since visual function can be impacted as well. Current treatment options for Dry Eye Disease leave too many patients untreated and unsatisfied,” said Christian Roesky, CEO of [Novaliq GmbH](#). “With our drugs in late-stage clinical development, we will redefine how DED is treated.”

Christian Roesky will speak at the Ophthalmology Futures Forums, September 20th, 2018 in Vienna, Austria. For further information, please send an email to event@novaliq.com.

About Novaliq

Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of eye patients: NovaTears® improves the signs and symptoms of dry eye disease (DED) and is marketed under CE approval in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Two drugs are in the late stage of clinical development with results expected in Q3 2018:

- CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability, is being evaluated in the pivotal phase 2b/3 ESSENCE trial.
- NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is being evaluated in the phase 2 SEECASE trial.

Headquartered in Heidelberg, Germany, Novaliq has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.

More on www.novaliq.com

Sources:

- 1) Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026, Published June 2018 by Global Data
- 2) Karakus S et al; Ophthalmology 2018, 125: 1500-1505
- 3) Koh S; Cornea 2016, 35: S83-S88

Media Contact:

Novaliq GmbH
Heidrun Kirsch
VP Marketing
hkirsch@novaliq.com